{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:58:35Z","timestamp":1781668715894,"version":"3.54.5"},"reference-count":12,"publisher":"Norwegian Medical Association","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2010,8,26]]},"DOI":"10.4045\/tidsskr.09.0722","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T07:59:59Z","timestamp":1283327999000},"page":"1624-6","source":"Crossref","is-referenced-by-count":0,"title":["Tigesyklin \u2013 et nytt antibiotikum"],"prefix":"10.4045","volume":"130","author":[{"given":"Venke","family":"Skibeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Aal\u00f8kken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egil","family":"Lingaas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Midtvedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Ola","family":"Solberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil K.","family":"Melby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"European Medicines Agency. European public assessment report (EPAR) \u2013 Tygacil. www.ema.europa.eu\/humandocs\/Humans\/EPAR\/tygacil (30.7. 2010)."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Doan T-L, Fung HB, Mehta D et al. Tigecycline: A\u00a0glycylcycline antimicrobial agent. Clin Ther 2006; 8: 1079\u2009\u2013\u2009106. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16982286&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.clinthera.2006.08.011","DOI":"10.1016\/j.clinthera.2006.08.011"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Peterson LR. A review of tigecycline \u2013 the first glycylcycline. Int J Antimicrob Agents 2008; 32 (suppl 4): S215\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19134522&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0924-8579(09)70005-6","DOI":"10.1016\/S0924-8579(09)70005-6"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Oliva ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5: 88. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16236177&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186\/1471-2334-5-88","DOI":"10.1186\/1471-2334-5-88"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41(suppl 5): S341\u2009\u2013\u200953. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16080072&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1086\/431675","DOI":"10.1086\/431675"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Breedt J, Teras J, Gardovskis J et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658\u2009\u2013\u200966. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16251309&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1128\/AAC.49.11.4658-4666.2005","DOI":"10.1128\/AAC.49.11.4658-4666.2005"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Slover CM, Rodvold KA, Danziger LH. Tigecycline: A novel broad-spectrum antimicrobial. Ann Pharmacother 2007; 41: 965\u2009\u2013\u200972. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17519296&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1345\/aph.1H543","DOI":"10.1345\/aph.1H543"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Rubinstein E, Vaughan D. Tigecycline: a novel glycylcycline. Drugs 2005; 65: 1317\u2009\u2013\u200936. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15977966&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00003495-200565100-00002","DOI":"10.2165\/00003495-200565100-00002"},{"key":"ref=9","unstructured":"Legemiddelverket. Legemiddels\u00f8k. Tygacil (tigecyclin). www.legemiddelverket.no (27.5.2010)."},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Barbour A, Schmidt S, Ma B et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet 2009; 48: 575\u2009\u2013\u200984. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19725592&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/11317100-000000000-00000","DOI":"10.2165\/11317100-000000000-00000"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Insa R, Cercenado E, Goyanes MJ. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007; 59: 583\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17213264&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093\/jac\/dkl496","DOI":"10.1093\/jac\/dkl496"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Nord CE, Sillerstr\u00f6m E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50: 3375\u2009\u2013\u200980. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17005820&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1128\/AAC.00373-06","DOI":"10.1128\/AAC.00373-06"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:37:07Z","timestamp":1781667427000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2010\/08\/legemidler-i-praksis\/tigesyklin-et-nytt-antibiotikum"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,26]]},"references-count":12,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2010,8,26]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.09.0722","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,26]]}}}